These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 15734046)

  • 1. Mucosal adjuvants.
    Freytag LC; Clements JD
    Vaccine; 2005 Mar; 23(15):1804-13. PubMed ID: 15734046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
    Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of CpG oligodeoxynucleotides as mucosal adjuvants.
    McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
    Crit Rev Immunol; 2001; 21(1-3):103-20. PubMed ID: 11642598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.
    Klinman DM; Klaschik S; Sato T; Tross D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):248-55. PubMed ID: 19272313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
    Hickey DK; Aldwell FE; Beagley KW
    Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel strategies using DNA for the induction of mucosal immunity.
    McCluskie MJ; Davis HL
    Crit Rev Immunol; 1999; 19(4):303-29. PubMed ID: 10530431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice.
    Nyström-Asklin J; Adamsson J; Harandi AM
    Scand J Immunol; 2008 May; 67(5):431-40. PubMed ID: 18298617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of mucosal immune responses by intranasal co-delivery of Newcastle disease vaccine plus CpG oligonucleotide in SPF chickens in vivo.
    Zhang L; Zhang M; Li J; Cao T; Tian X; Zhou F
    Res Vet Sci; 2008 Dec; 85(3):495-502. PubMed ID: 18359498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa.
    Cox E; Verdonck F; Vanrompay D; Goddeeris B
    Vet Res; 2006; 37(3):511-39. PubMed ID: 16611561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of CpG oligodeoxynucleotides as immune adjuvants.
    Klinman DM; Currie D; Gursel I; Verthelyi D
    Immunol Rev; 2004 Jun; 199():201-16. PubMed ID: 15233736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of CpG DNA as a mucosal vaccine adjuvant.
    McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
    Curr Opin Investig Drugs; 2001 Jan; 2(1):35-9. PubMed ID: 11527008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.
    Didierlaurent AM; Morel S; Lockman L; Giannini SL; Bisteau M; Carlsen H; Kielland A; Vosters O; Vanderheyde N; Schiavetti F; Larocque D; Van Mechelen M; Garçon N
    J Immunol; 2009 Nov; 183(10):6186-97. PubMed ID: 19864596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
    Mutwiri G; Benjamin P; Soita H; Babiuk LA
    Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADP-ribosylating enterotoxins as vaccine adjuvants.
    Lycke N; Lebrero-Fernández C
    Curr Opin Pharmacol; 2018 Aug; 41():42-51. PubMed ID: 29702466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant properties of CpG oligonucleotides in primates.
    Verthelyi D
    Methods Mol Med; 2006; 127():139-58. PubMed ID: 16988453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand.
    Salucci V; Mennuni C; Calvaruso F; Cerino R; Neuner P; Ciliberto G; La Monica N; Scarselli E
    Scand J Immunol; 2006 Jan; 63(1):35-41. PubMed ID: 16398699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments in mucosal immunomodulatory adjuvants.
    Harandi AM; Sanchez J; Eriksson K; Holmgren J
    Curr Opin Investig Drugs; 2003 Feb; 4(2):156-61. PubMed ID: 12669375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholera toxin and related enterotoxins: a cell biological and immunological perspective.
    de Haan L; Hirst TR
    J Nat Toxins; 2000 Aug; 9(3):281-97. PubMed ID: 10994530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A two-codon mutant of cholera toxin lacking ADP-ribosylating activity functions as an effective adjuvant for eliciting mucosal and systemic cellular immune responses to peptide antigens.
    Lomada D; Gambhira R; Nehete PN; Guhad FA; Chopra AK; Peterson JW; Sastry KJ
    Vaccine; 2004 Dec; 23(4):555-65. PubMed ID: 15530705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.